- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06936683
Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia(the HSV-SP Study)
April 22, 2025 updated by: Second Affiliated Hospital of Guangzhou Medical University
Prognostic Effect of Herpes Simplex Virus Type 1 Infection/Reactivation in the Lower Respiratory Tract of Critical Care Patients With Severe Pneumonia(the HSV-SP Study): a Study Protocol for a Multicenter, Prospective Cohort Study
Severe pneumonia(SP) is a one of the main causes of death for critically ill patients.Samples of bronchoalveolar lavage fluid (BALF) from SP patients often report positive for herpes simplex virus type 1 (HSV-1) DNA.
However, to date, it is unclear the impact and significance of this positive result on SP patients.
This study will evaluate the prognostic impact of lower respiratory tract HSV-1 infection/reactivation on ICU severe pneumonia patients.At the same time, by analyzing the risk factors that affect prognosis, we will identify populations with the potential for intervention benefits and provide a basis for further intervention treatment.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
323
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lili L Tao
- Phone Number: +8613535107553
- Email: taollicu@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Study Population Description :Patients with age>18 years old admitted to the ICU who meet the diagnostic criteria for severe pneumonia.
Description
Inclusion Criteria:
- 1: Age>18 years old. 2: Clinical diagnosis for severe pneumonia. 3: ICU stay time >72 hours. 4: A written informed consent form was obtained from the members of the patients' family.
Exclusion Criteria:
- 1: severe ventilation dysfunction, and effective respiratory support has not been used; 2: Aortic aneurysm and esophageal varices at risk of rupture; 3: Recent acute coronary syndrome, uncontrolled severe hypertension, and malignant arrhythmia; 4: Irreversible bleeding tendencies, such as severe coagulation dysfunction, massive hemoptysis, or gastrointestinal bleeding; 5: Multiple pulmonary bullae at risk of rupture. 6: Estimated survival time<24 hours. 7: Included in another interventional clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
30 day mortality rate of critical care patients with severe pneumonia.
Time Frame: From enrollment (Day 1) through Day 30
|
From enrollment (Day 1) through Day 30
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence rate of herpes simplex virus type 1 infection/reactivation in the lower respiratory tract of critical care patients with severe pneumonia
Time Frame: From enrollment (Day 1) through Day 30
|
From enrollment (Day 1) through Day 30
|
|
ICU mortality and in-hospital mortality , ICU stay time and length of in-hospital stay
Time Frame: From enrollment (Day 1) through the entire ICU stays and in-hospital stays
|
From enrollment (Day 1) through the entire ICU stays and in-hospital stays
|
|
success rate of ventilator withdrawal, ICU non ventilator survival time
Time Frame: From enrollment (Day 1) through Day 30
|
From enrollment (Day 1) through Day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2025
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
October 1, 2027
Study Registration Dates
First Submitted
April 14, 2025
First Submitted That Met QC Criteria
April 14, 2025
First Posted (Actual)
April 20, 2025
Study Record Updates
Last Update Posted (Actual)
April 25, 2025
Last Update Submitted That Met QC Criteria
April 22, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Virus Diseases
- Respiratory Tract Diseases
- Lung Diseases
- DNA Virus Infections
- Skin Diseases
- Skin Diseases, Infectious
- Herpesviridae Infections
- Skin Diseases, Viral
- Pneumonia
- Infections
- Herpes Simplex
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Dimercaprol
Other Study ID Numbers
- MR-44-24-013041
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.